MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
2.430
+0.110
+4.74%
After Hours: 2.440 +0.01 +0.41% 18:40 01/27 EST
OPEN
2.290
PREV CLOSE
2.320
HIGH
2.525
LOW
2.290
VOLUME
2.81M
TURNOVER
0
52 WEEK HIGH
15.20
52 WEEK LOW
1.570
MARKET CAP
229.58M
P/E (TTM)
-0.8398
1D
5D
1M
3M
1Y
5Y
BRIEF-Millennium Management Llc Reports 5.1% Passive Stake In Gossamer Bio Inc As Of December 29 - SEC Filing
Reuters · 01/04 21:50
Looking Into Gossamer Bio's Recent Short Interest
Benzinga · 01/03 16:36
180 Life Sciences, KalVista top healthcare gainers; Edesa, Nutex among losers
Seekingalpha · 12/27/2022 15:02
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 12/22/2022 17:32
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Benzinga · 12/08/2022 13:04
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $5
Benzinga · 12/08/2022 11:24
HC Wainwright Adjusts Gossamer Bio's Price Target to $5 From $25, Keeps Buy Rating
HC Wainwright Adjusts Gossamer Bio's Price Target to $5 From $25, Keeps Buy Rating
MT Newswires · 12/08/2022 08:31
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 12/07/2022 18:45
More
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).

Webull offers kinds of Gossamer Bio Inc stock information, including NASDAQ:GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.